Recent developments in our knowledge of the immune system, the bone marrow micro-environment and the genetic evolution of MDS are optimizing prognostication and management strategies. Intrinsic and extrinsic factors contributing to disease pathogenesis and influencing therapeutic response will be discussed.
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
Upon completion of the educational activity, participants should be able to:
Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Director of MDS Research Program and Head of National MDS registry
Head, Hematology Site Group
Odette Cancer Center
Professor of Hematology
Department of Molecular Medicine, University of Pavia
Chief, Division of Hematology
Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo
Professor of Personalised Cancer Medicine
Queen Mary University of London
London, United Kingdom
Leukemia and MDS Section Head
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
King’s College Hospital and King’s College London
Department of Haematological Medicine
London, United Kingdom
Associate Professor, Harvard Medical School
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Hematology
University of Pavia
Department of Hematology Oncology & Molecular Medicine
|7:00 – 7:30 am||Complimentary Breakfast
|7:30 – 7:40 am||Program Overview and Objectives
Stephen Nimer, MD
|7:40 – 8:15 am||Myeloid Neoplasms with Germline Predisposition
Jude Fitzgibbon, PhD
|8:15 – 8:50 am||Clonal Cytopenia and Myeloid Neoplasms
Luca Malcovati, MD
|8:50 – 9:25 am||Abnormalities of the Immune System and Inflammation in MDS Pathogenesis
Shahram Kordasti, MD, PhD
|9:25 – 10:00 am||Therapies for Higher Risk MDS Patients: Optimizing HMA Approaches and Use of Novel Agents
Rami Komrokji, MD
|10:00 – 10:35 am||Maximizing Success: Optimizing Prognostication and Timing of Allogeneic Stem Cell Transplant for MDS
John Koreth, MD, PhD
|10:35 – 11:00 am||Questions/Answers/Discussion
Rena Buckstein, MD, FRCPC
Mario Cazzola, MD
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at the conclusion of the live program on this page https://www.mds-foundation.org/learning-center/mds-2017/. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CME/CE activity, please contact AKH Inc. at email@example.com.
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF). AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge- based activity for 3.5 contact hour(s) (0.35 CEUs). UAN 0077-9999-16-103-L04-P.
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 3.5 Contact Hours.
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF).
This activity is supported by an educational grant from Celgene Corporation, Onconova Therapeutics, Inc. and Takeda Oncology.
AMERICANS WITH DISABILITIES ACT
AKH Inc, Advancing Knowledge in Healthcare fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify AKH at 904-683-8843 at least two weeks prior to the activity.
*Activity and faculty subject to change